^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non Small Cell Lung Cancer
    Drug:ficonalkib (SY-3505) (ALK inhibitor, LTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

    Excerpt:
    ...Agree to provide fresh tumor tissue samples to test positive for ALK fusion (ALK-positive) by the central laboratory: 1....
    Trial ID:
    NCT05869162
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

    Excerpt:
    ...Dose-escalation phase: patients must have histological or cytological confirmed ALK-positive advanced NSCLC....
    Trial ID:
    NCT05257512
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Efficacy and safety of SY-3505, a third-generation ALK TKI, in ALK-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.

    Published date:
    05/25/2023
    Excerpt:
    SY-3505 was well-tolerated and showed significant and durable clinical activity in ALK-positive NSCLC patients…
    DOI:
    10.1200/JCO.2023.41.16_suppl.9110
    Trial ID:
    NCT05257512